Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.

ABSTRACT:

Purpose

Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia development and maintenance, and thus sensitive to small-molecule inhibitors that target epigenetic mechanisms.

Experimental design

A panel of B-ALL cell lines was tested for sensitivity to HDACi with varying isoform sensitivity. Isoform-specific shRNAs were used as further validation of HDACs as relevant therapeutic targets in B-ALL. Mouse xenografts of B-cell malignancy-derived cell lines and a pediatric B-ALL were used to demonstrate pharmacologic efficacy.

Results

Nonselec

SUBMITTER: Stubbs MC 

PROVIDER: S-EPMC4433811 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature